GlassScriptPhysician profile
Heather I Prince
NPI 1174081657
$4,514.94
in general payments reported to CMS, 2019-2025
16 companies · $1,952 in 2025
The $1,952 reported for 2025 was more than what 95% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $693 · 2024: $1,870 · 2025: $1,952.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,515.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,514.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,138.63 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $1,096.14 | 2023-2025 | Airsupra, Breztri, Fasenra |
| Novo Nordisk INC | $935.79 | 2023-2025 | Wegovy, Ozempic, Rybelsus |
| Dexcom, INC. | $296.64 | 2024-2025 | Dexcom G6 Transmitter |
| Exact Sciences Corporation | $214.13 | 2023-2025 | Cologuard Collection Kit |
| Phathom Pharmaceuticals, INC. | $201.24 | 2023-2024 | Voquezna |
| Abbott Laboratories | $182.97 | 2024 | Freestyle Libre 3 |
| Axsome Therapeutics, INC. | $114.82 | 2025 | Symbravo |
| Lilly USA, LLC | $72.45 | 2023-2025 | Mounjaro |
| Merck Sharp & Dohme LLC | $70.06 | 2024-2025 | Capvaxive, Gardasil 9, Gardasil |
| Circassia INC. | $50.76 | 2025 | Niox |
| Dynavax Technologies Corporation | $50.25 | 2023-2024 | Heplisav-B |
| Takeda Pharmaceuticals U.S.A., INC. | $31.25 | 2024 | Trintellix |
| Irhythm Technologies, INC. | $20.41 | 2024 | Zio Xt Patch, Zio Monitor |
| Pfizer INC. | $19.99 | 2024 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $19.41 | 2023 | Trulance, Xifaxan |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Heather Prince listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.